Zhang Cunliang, Guan Zhong, Peng Jieren
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2015 Jan;29(2):102-7.
In this study, we have detected the expression of STC2 protein in laryngeal cancer and The safe incisal margin by immunohistochemical staining, to evaluate its correlation with clinical features and the prognosis value in laryngeal squamous cell cancer.
Eighty-one paraffin-embedd specimens of patients who underwent surgery for laryngeal cancer were collected. Clinical data, including date of birth, gender, tumor subsite, tumor stage, RT, and survival status have been recorded. The samples including laryngeal cancer tissues and the safe incisal margin were analyzed for the expression of STC2 protein by immunohistochemical staining. We analyzed the correlations with STC2 expression level and clinical data with software SPSS 18. 0.
(1)fifty-six cases in 81 cases (69. 1 %) are positive. In 30 cases of the safe incisal margin tissues, STC2 is not expressed, which shows statistically significant differences between the two groups (P<0. 05). (2)Overexpression of STC2 in laryngeal cancer were correlated with the tumor clinical stage and N stage, T stage, tumor site location and histological grade (P<0. 05), but not with genderor age (P> 0. 05). (3)The result showed that the 3-year survival rate is 74. 1%, according to the survival analysis by STC2, STC2 positive group has poorer outcome versus the negative group. (4)The clinical stage displayed the independent value in predicting the tumor prognosis of laryngeal cancer (P<0. 05), not the expression level of STC2.
Overexpression of STC2 in laryngeal cancer patients is correlated with poor outcome, which means STC2 positive group has poorer prognosis than the STC2 negative group.
本研究通过免疫组织化学染色检测喉癌组织中STC2蛋白的表达及安全切缘情况,以评估其与临床特征的相关性及在喉鳞状细胞癌中的预后价值。
收集81例接受喉癌手术患者的石蜡包埋标本,记录患者的临床资料,包括出生日期、性别、肿瘤部位、肿瘤分期、放疗情况及生存状态。采用免疫组织化学染色法分析喉癌组织及安全切缘标本中STC2蛋白的表达情况,应用SPSS 18.0软件分析STC2表达水平与临床资料的相关性。
(1)81例中有56例(69.1%)呈阳性。30例安全切缘组织中STC2未表达,两组间差异有统计学意义(P<0.05)。(2)喉癌中STC2的过表达与肿瘤临床分期、N分期、T分期、肿瘤部位及组织学分级相关(P<0.05),但与性别和年龄无关(P>0.05)。(3)结果显示3年生存率为74.1%,经STC2生存分析,STC2阳性组预后较阴性组差。(4)临床分期在预测喉癌肿瘤预后方面具有独立价值(P<0.05),而不是STC2的表达水平。
喉癌患者中STC2过表达与预后不良相关,即STC2阳性组预后比STC2阴性组差。